25 Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)
Abstract Background SMARCB1-deficient renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma (RCC) that predominantly affects young individuals of African descent harboring sickle hemoglobinopathies (Msaouel et al. Clin Cancer Res 2018, PMID: 29440190). All cases are defined by loss of the SMARCB1...